Suven Life Sciences will be a tonic in portfolio
Suven life sciences at Rs 170, promises to defy gravity as it has reached the bottom.
Scrip has fully bottomed out, resting on 200 Week MA.
It is also in a declining triangle, with a firm flat support between 148 ~ 163.
It needs a volume breakout, although pricewise it has reared its head up at Rs 170 now.
Catch in an infant stage is what it is presently appearing and once pharma industry develops fancy - which it should now soon anytime - with stabilisation of Trump's policies, it will race ahead dramatically.
All fundamental parameters are encouraging. Rs. 220 would be the first strong resistance and thereafter I daresay, Rs 445 may not be far away - say in a year's time frame !!!
Just Buy and hold with a stoploss of Rs 148.
Scrip has fully bottomed out, resting on 200 Week MA.
It is also in a declining triangle, with a firm flat support between 148 ~ 163.
It needs a volume breakout, although pricewise it has reared its head up at Rs 170 now.
Catch in an infant stage is what it is presently appearing and once pharma industry develops fancy - which it should now soon anytime - with stabilisation of Trump's policies, it will race ahead dramatically.
All fundamental parameters are encouraging. Rs. 220 would be the first strong resistance and thereafter I daresay, Rs 445 may not be far away - say in a year's time frame !!!
Just Buy and hold with a stoploss of Rs 148.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。